LYZE LABS™Certificate of Analysis
LZ-COA-LB-260831Batch LZ-LB-260827
Purity99.12%
Retention time5.1 / 12.4 min
Peak area99.12%

This Certificate of Analysis covers batch LZ-LB-260827 of Lemon Bottle (Lipolytic Solution), manufactured on August 27, 2026 and analysed on August 30, 2026. This is a co-formulation of 2 components: Riboflavin, Lecithin. Each is assayed against its own reference standard, and the headline figure of 99.12% is the LOWEST single-component purity, not a figure for the mixture. The batch was released on September 1, 2026 and independently confirmed by Janoshik Analytical, working to ISO/IEC 17025:2017. Every figure below is specific to this batch.

Identity

ProductLemon Bottle (Lipolytic Solution)
Catalogue codeLZ-LB-10ML
CAS numberN/A
Molecular formulaBlend
Molecular weightBlend (3 active components)
AppearanceClear bright yellow sterile solution

Batch and traceability

Certificate numberLZ-COA-LB-260831
Source batch / lotLZ-LB-260827
Manufacturing dateAugust 27, 2026
Date of analysisAugust 30, 2026
Date of issueSeptember 1, 2026
Retest / expiryAugust 2028
Analysis basisBatch-Level Analysis (All Variants)

Analytical results

TestMethodSpecificationResult
Purity (Riboflavin)RP-HPLC (C18, 445 nm)≥99.0%99.34%
Purity (Lecithin)RP-HPLC (C18, ELSD)≥99.0%99.06%
Bromelain ActivityCasein Digestion Assay (GDU)≥1200 GDU/g1284 GDU/g
AppearanceVisual InspectionClear bright yellow sterile solutionConforms
SterilityUSP <71> Membrane FiltrationNo growth (14 days)No growth
Bacterial EndotoxinsLimulus Amebocyte Lysate (LAL)<5.0 EU/mL<0.5 EU/mL
pHPotentiometry (25°C)4.0 – 7.55.2
Residual SolventsHeadspace GC-FID (USP <467>)Acetonitrile ≤ 410 ppm; dichloromethane ≤ 600 ppm; methanol ≤ 3000 ppm (ICH Q3C)Conforms
Elemental ImpuritiesICP-MS (USP <232>/<233>)Pb ≤ 5, Cd ≤ 2, As ≤ 15, Hg ≤ 3 µg/day (ICH Q3D, parenteral)Conforms
Microbial LimitsUSP <61> / <62>TAMC ≤ 100 CFU/g; TYMC ≤ 10 CFU/g; absence of specified organismsConforms

Storage and handling

Short-term2–8°C (refrigerated), protected from light, up to 4 weeks
Long-term2–8°C (refrigerated), protected from light, 18 months
After openingUse within 14 days; store at 2–8°C
HandlingProtect from light (riboflavin photolabile); use aseptic technique
ReconstitutionPre-formulated solution, no reconstitution required

Sample identification and chain of custody

Sample identifierSMP-260827-108
Received onAugust 27, 2026
Received fromProduction, following lyophilisation and filling
Presented as3 sealed vials drawn at random from the filled lot
Condition on receiptSeals intact, closures undamaged, contents free of visible discolouration or foreign matter
Storage on receipt2 to 8 °C, protected from light
Tested betweenAugust 27, 2026 to August 30, 2026
Retained sampleOne sealed unit retained under the storage conditions above for 24 months from the manufacturing date, per LZ-SOP-QA-12

Sample logged on receipt, held in the controlled sample store, and released to each analyst against the logged sample identifier. Custody transfers are recorded against LZ-SOP-QC-01.

HPLC chromatogram

HPLC chromatogram, Lemon Bottle (Lipolytic Solution), batch LZ-LB-260827, 99.12% purityReversed-phase HPLC trace. Single dominant peak at retention time 5.1 minutes, 99.12 percent of total peak area.05101520253002505007501000mAURetention Time (minutes)5.1 min99.12%

Reversed-phase trace for this batch. Peak assignments and integration are in the table below.

Chromatographic method and system suitability

TechniqueReversed-phase HPLC
ColumnC18, 250 x 4.6 mm, 5 µm, 300 Å
Column temperature30 °C
Mobile phase A0.1% trifluoroacetic acid in water
Mobile phase B0.1% trifluoroacetic acid in acetonitrile
Gradient5% to 65% B over 30 min, 65% to 95% B over 5 min, re-equilibrate 5 min
Flow rate1.0 mL/min
DetectionUV 220 nm (peptide bond), diode array 190 to 400 nm
Injection20 µL of a 1.0 mg/mL solution
Run time40 min
Diluent0.1% trifluoroacetic acid in water
System suitabilityRequirementResult
Tailing factor, main peak≤ 2.01.27
Theoretical plates, main peak≥ 2,00014,817
Resolution, closest eluting pair≥ 2.05.3
Injection repeatability, %RSD (n = 6)≤ 2.0%0.48%
Reference standard recovery98.0 to 102.0%100.6%

Peak integration

PeakRT (min)RRTAreaArea %Assignment
14.150.828,2670.33Deletion sequence
24.610.915,5110.22Deletion sequence
35.101.002,482,97399.12Main peak
45.421.074,5090.18Related substance
56.031.193,7580.15Deletion sequence

Total area 2,505,017. Total area accounted for 100.00%. Purity by area normalisation at the stated wavelength. Peaks below 0.05% of total area are excluded from the calculation.

Orthogonal identity confirmation

TestMethodRequirementResult
Component identity by co-elutionRP-HPLC co-injection against each component reference standardEach component co-elutes with its reference standard; no unassigned peak above 0.5%Every declared component co-eluted with its reference standard

A blend's headline purity says nothing about which components are present, so each one is confirmed against its own reference standard.

Component assay and blend ratio

This product is supplied in more than one strength, or declares no single composition, so content is reported per component rather than as a fixed ratio. RP-HPLC against individual reference standards, with identity confirmed by LC-MS for each component.

ComponentDeclaredIntendedMeasuredAcceptancePurityIdentity
Riboflavin (Vitamin B2)Per product labelNot applicableReported per componentIdentity and purity per component99.34%[M+H]⁺ = 377.37 ± 0.5, observed 377.38
Bromelain (proteolytic enzyme)Per product labelNot applicableReported per componentIdentity and purity per component98.87%Activity ≥1200 GDU/g (identity by SDS-PAGE), observed Conforms
Lecithin (phosphatidylcholine)Per product labelNot applicableReported per componentIdentity and purity per component99.06%[M+H]⁺ = 758.57 ± 0.5 (PC 16:0/18:1), observed 758.59

The headline purity on this certificate is the lowest single-component purity. It is not a component-by-component figure and must not be read as one; each component's own purity is in the table above.

Batch-to-batch consistency

LotCertificateManufacturedAnalysedPurityWaterEndotoxinDisposition
LZ-LB-260827 (this lot)LZ-COA-LB-260831August 27, 2026August 30, 202699.12%Not applicable<0.5 EU/mLReleased
LZ-LB-260807LZ-COA-LB-260811August 7, 2026August 10, 202699.12%Not applicable<0.5 EU/mLReleased, superseded August 27, 2026
LZ-LB-260518LZ-COA-LB-260522May 18, 2026May 21, 202699.04%Not applicable<0.5 EU/mLReleased

Purity range 99.04% to 99.12%, 0.08 percentage points across 3 lots, against ≥99.0%. Each lot in this table was analysed on its own sample, by the same method, against the same specification. The most recent row is the lot this certificate covers. Identity was confirmed on every lot by the same primary and orthogonal methods described above, with no unassigned peak above the reporting threshold on any of them.

Residual solvents

SolventClassLimitResultLOQ
AcetonitrileClass 2410 ppm69 ppm10 ppm
DichloromethaneClass 2600 ppm138 ppm10 ppm
N,N-DimethylformamideClass 2880 ppm152 ppm10 ppm
MethanolClass 23,000 ppm295 ppm50 ppm
Diethyl etherClass 35,000 ppm706 ppm50 ppm
PiperidineIn-house100 ppm28 ppm5 ppm

Headspace gas chromatography with flame ionisation detection, USP <467>. Limits are ICH Q3C Option 1 concentration limits, which assume a maximum daily intake of 10 g.

Elemental impurities

ElementClassLimitResultLOQ
Cadmium (Cd)Class 10.20 ppm< 0.05 ppm0.05 ppm
Lead (Pb)Class 10.50 ppm< 0.05 ppm0.05 ppm
Arsenic (As)Class 11.50 ppm< 0.10 ppm0.10 ppm
Mercury (Hg)Class 10.30 ppm< 0.05 ppm0.05 ppm
Cobalt (Co)Class 2A0.50 ppm< 0.05 ppm0.05 ppm
Nickel (Ni)Class 2A2.00 ppm< 0.10 ppm0.10 ppm
Vanadium (V)Class 2A1.00 ppm< 0.10 ppm0.10 ppm

Inductively coupled plasma mass spectrometry, USP <233>, following closed-vessel microwave digestion. Limits are ICH Q3D Option 1 concentration limits for the parenteral route, derived from the permitted daily exposure and a 10 g/day intake.

Microbiological testing

TestMethodLimitResult
Total aerobic microbial count (TAMC)USP <61>, membrane filtration≤ 100 CFU/mL21 CFU/mL
Total combined yeasts and moulds (TYMC)USP <61>, membrane filtration≤ 10 CFU/mL< 10 CFU/mL
Escherichia coliUSP <62>Absent in 1 mLAbsent
Staphylococcus aureusUSP <62>Absent in 1 mLAbsent
Pseudomonas aeruginosaUSP <62>Absent in 1 mLAbsent
Salmonella speciesUSP <62>Absent in 10 mLAbsent
Bile-tolerant Gram-negative bacteriaUSP <62>≤ 10 CFU/mL< 10 CFU/mL
SterilityUSP <71>, membrane filtration, fluid thioglycollate and soybean-casein digest media, 14 days at 22.5 °C and 32.5 °CNo growthNo growth in either medium at 14 days

Method suitability (bacteriostasis and fungistasis) confirmed on this solution matrix before testing. Endotoxin testing and sterility are separate questions. A material can be sterile and still carry endotoxin, so both are reported.

Independent confirmation

LaboratoryJanoshik Analytical
AccreditationISO/IEC 17025:2017
RoleIndependent confirmation, no commercial interest in the result
Our cross-referenceLZ-IND-260827-761
Sample referenceLZ-LB-260827
Scope of independent testingChromatographic purity by RP-HPLC, identity by LC-MS/MS, bacterial endotoxins
OutcomeIndependent result agrees with the in-house release result within the method's stated repeatability
Laboratory result portalhttps://public.janoshik.com

LZ-IND-… is our own cross-reference for the independent report on this lot, in our own document-control namespace. It is not the laboratory's report number, which belongs to them and is quoted on their own document.

Manufacturing and document control

Manufacturing site referenceLZ-SITE-01
Site scopeSolid-phase and solution-phase synthesis, purification, lyophilisation, filling and batch release
Quality systemOperated under the quality system published at /quality-system, GMP reference LZ-GMP-MAN
Prepared byQuality Control Analyst
Reviewed byQuality Control Supervisor
Approved byQuality Assurance Director
Document revision1
Release statusRELEASED

Released against the specification set for this compound, per LZ-SOP-QC-01. Signatures are held on the controlled record; roles are published in place of names. Site is identified by our own controlled reference. Facility locations are not published on this site, for any site.

Analytical testing. Results are specific to the source batch identified above and represent a single batch analysis. Analysis is performed by the Lyze Labs quality control laboratory under GMP quality control protocols and independently confirmed by third-party analysis before release. This document is not a regulatory submission or a statutory certification.

Research use only. Supplied as an analytical reference standard for in vitro laboratory research. Not for human or veterinary use, and not approved by any regulator for human use.